Crescent Biopharma reports Q2 results

21 hours ago 1

Crescent Biopharma, Inc. press release (NASDAQ:CBIO): Q2 Net loss was $21.8 million, or $4.93 per basic and diluted share.
Cash was $152.6 million as of June 30, 2025, which is anticipated to fund operations through 2027.

Recommended For You